Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. (January 2022)

• Record Type: Journal Article
• Authors: Kreitman, Robert J.; Arons, Evgeny
• Is Part Of: Blood reviews. Volume 51(2022)
• Publication Date: 2022-01
• Subjects: Hairy cell leukemia -- Treatment -- Cladribine -- Rituximab -- Vemurafenib -- Dabrafenib -- Trametinib -- Moxetumomab pasudotox -- Minimal residual disease; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2021.100888
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1 st -line and relapsed settings. BRAF inhibitors and Ibrutinib can achieve remission, but due to persistence of MRD, must be used chronically to prevent relapse. BRAF inhibition combined with Rituximab can achieve high MRD-free CR rates. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox is FDA-approved in the relapsed setting and is unique in achieving high MRD-free CR rates as a single-agent. Avoiding chemotherapy and rituximab may be important in ensuring both recovery from COVID-19 and successful COVID-19 vaccination, an area of continued investigation.